Eli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche's Tarceva in first-line non-small cell lung cancer with EGFR mutations, paving the way for filings with ...
Chugai Pharmaceutical Co., Ltd. and Cheplapharm K.K. announced that Chugai will transfer the business in Japan concerning the anti-cancer agent Tarceva tablets 25, 100, and 150 to Cheplapharm. Chugai ...
Roche's Tarceva and AstraZeneca's own Iressa are the current standard of care in first line treatments of patients with locally advanced or metastatic EGFR+ lung cancer, but Tagrisso looks set to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback